Business
Replimune To Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Presentations include recently updated results from the skin cancer cohort of IGNYTE, an ongoing Phase 1/2 study of RP1 combined with Opdivo® (nivolumab), and
About this update from Replimune Group, Inc.
[{"type":"text","content":"Presentations include recently updated results from the skin cancer cohort of IGNYTE, an ongoing Phase 1/2 study of RP1 combined with Opdivo® (nivolumab), and trial-in-progress updates across the RP1, RP2 and RP3 programs\nWOBURN, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced multiple presentations at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, IL from June 3 to June 7, 2022. Details for the presentations are as follows: Data presentation Updated results from the skin cancer cohorts from an ongoing Phase 1/2 multi-cohort study of RP1, an enhanced potency oncolytic HSV, combined with nivolumab (IGNYTE) Session Title: Melanoma/Skin CancersSession Date and Time: Monday, June 6, 2022, 1:15 PM-4:15 PM CDTLocation: McCormick Place, Exhibit Hall A, Poster 146Abstract: 9553 Trial in progress presentations A randomized, controlled, open-label, phase 2 study of cemiplimab ± RP1 in patients with advanced cutaneous squamous cell carcinoma (CERPASS) Session Title: Melanoma/Skin CancersSession Date and Time: Monday, June 6, 2022, 1:15 PM-4:15 PM CDTLocation: McCormick Place, Exhibit Hall A, Poster 184aAbstract: TPS9593 An open-label, multicenter, phase 1b/2 study of RP1, a first-in-class, enhanced potency oncolytic virus in solid organ transplant recipients with advanced cutaneous malignancies (ARTACUS) Session Title: Melanoma/Skin CancersSession Date and Time: Monday, June 6, 2022, 1:15 PM-4:15 PM CDTLocation: McCormick Place, Exhibit Hall A, Poster 187aAbstract: TPS9597 A phase 1 trial of RP2, a first-in-class, enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody as a single agent and combined with nivolumab in patients with advanced solid tumors Session Title: Developmental Therapeutics ImmunotherapySession Date and Time: Sunday, June 5, 2022, 8:00 AM-11:00 AM CDTLocation: McCormick Place, Exhibit Hall A, Poster 339bAbstract: TPS2704 An open-label, multicenter, phase 1 study of RP3 as a single agent and in combination with nivolumab in patients (pts) with solid tumors Session Title: Developmental Therapeutics ImmunotherapySession Date and Time: Sunday, June 5, 2022, 8:00 AM-11:00 AM CDTLocation: McCormick P...